186 related articles for article (PubMed ID: 34638502)
41. A differential risk assessment and decision model for Transarterial chemoembolization in hepatocellular carcinoma based on hepatic function.
Nam JY; Choe AR; Sinn DH; Lee JH; Kim HY; Yu SJ; Kim YJ; Yoon JH; Lee JM; Chung JW; Choi SY; Lee JK; Baek SY; Lee HA; Kim TH; Yoo K
BMC Cancer; 2020 Jun; 20(1):504. PubMed ID: 32487089
[TBL] [Abstract][Full Text] [Related]
42. Development of a computed tomography-based radiomics nomogram for prediction of transarterial chemoembolization refractoriness in hepatocellular carcinoma.
Niu XK; He XF
World J Gastroenterol; 2021 Jan; 27(2):189-207. PubMed ID: 33510559
[TBL] [Abstract][Full Text] [Related]
43. A combination of the preoperative neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios as a useful predictor of survival outcomes following the transarterial chemoembolization of huge hepatocellular carcinoma.
Liu J; Zhang W; Niu R; Li Y; Zhou X; Han X
Saudi Med J; 2020 Apr; 41(4):376-382. PubMed ID: 32291424
[TBL] [Abstract][Full Text] [Related]
44. Validation of the Risk Prediction Models STATE-Score and START-Strategy to Guide TACE Treatment in Patients with Hepatocellular Carcinoma.
Mähringer-Kunz A; Kloeckner R; Pitton MB; Düber C; Schmidtmann I; Galle PR; Koch S; Weinmann A
Cardiovasc Intervent Radiol; 2017 Jul; 40(7):1017-1025. PubMed ID: 28197830
[TBL] [Abstract][Full Text] [Related]
45. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
46. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
Zhang Y; Miao H; Xie W; Jiang S; Song Z; Huang G; Fan W; Wang Y; Li J; Chen Y
Eur Radiol; 2021 Jan; 31(1):232-243. PubMed ID: 32728770
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of preoperative CALLY index for prognostication in patients with esophageal squamous cell carcinoma undergoing surgery.
Feng J; Wang L; Yang X; Chen Q
Sci Rep; 2024 Jan; 14(1):713. PubMed ID: 38184747
[TBL] [Abstract][Full Text] [Related]
48. Systemic inflammatory response predicts poor prognoses in Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma with transarterial chemoembolization: a prospective study.
Huang Z; Lu W; Yu N; Yang G; Xu H; Liu H
Transl Cancer Res; 2019 Nov; 8(7):2552-2563. PubMed ID: 35117012
[TBL] [Abstract][Full Text] [Related]
49. Prognostic Values of Inflammation-Based Scores and Fibrosis Markers in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Cho EJ; Yu SJ; Lee YB; Lee JH; Kim YJ; Yoon JH
Diagnostics (Basel); 2022 May; 12(5):. PubMed ID: 35626324
[TBL] [Abstract][Full Text] [Related]
50. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis.
Shen L; Chen S; Qiu Z; Qi H; Yuan H; Cao F; Xie L; Chen Q; Li W; Fan W
J Cancer Res Ther; 2020 Sep; 16(5):1063-1068. PubMed ID: 33004748
[TBL] [Abstract][Full Text] [Related]
51. CRP-albumin-lymphocyte (CALLY) Index Is an Independent Prognostic Factor for the Esophageal Cancer Patients Who Received Curative Treatment.
Aoyama T; Hashimoto I; Maezawa Y; Hara K; Kazama K; Komori K; Numata M; Tamagawa A; Fukuda M; Cho H; Morita J; Yoshizawa S; Otani K; Kato A; Tanabe M; Nakazono M; Kawahara S; Oshima T; Saito A; Yukawa N; Rino Y
Anticancer Res; 2024 Feb; 44(2):815-822. PubMed ID: 38307573
[TBL] [Abstract][Full Text] [Related]
52. Quantitative washout in patients with hepatocellular carcinoma undergoing TACE: an imaging biomarker for predicting prognosis?
Müller L; Hahn F; Jungmann F; Mähringer-Kunz A; Stoehr F; Halfmann MC; Pinto Dos Santos D; Hinrichs J; Auer TA; Düber C; Kloeckner R
Cancer Imaging; 2022 Jan; 22(1):5. PubMed ID: 35016731
[TBL] [Abstract][Full Text] [Related]
53. Prognostic factors and an innovative nomogram model for patients with hepatocellular carcinoma treated with postoperative adjuvant transarterial chemoembolization.
Xu JX; Qin SL; Wei HW; Chen YY; Peng YC; Qi LN
Ann Med; 2023 Dec; 55(1):2199219. PubMed ID: 37070467
[TBL] [Abstract][Full Text] [Related]
54. Safety, efficacy, and survival of drug-eluting beads-transarterial chemoembolization vs. conventional-transarterial chemoembolization in advanced HCC patients with main portal vein tumor thrombus.
Chen J; Lai L; Zhou C; Luo J; Wang H; Li M; Huang M
Cancer Imaging; 2023 Jul; 23(1):70. PubMed ID: 37481660
[TBL] [Abstract][Full Text] [Related]
55. Impact of C-reactive protein-albumin-lymphocyte (CALLY) index on prognosis after hepatectomy for colorectal liver metastasis.
Furukawa K; Tsunematsu M; Tanji Y; Ishizaki S; Akaoka M; Haruki K; Uwagawa T; Onda S; Matsumoto M; Ikegami T
Surg Oncol; 2023 Apr; 47():101911. PubMed ID: 36773544
[TBL] [Abstract][Full Text] [Related]
56. Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Rebonato A; Graziosi L; Maiettini D; Marino E; De Angelis V; Brunese L; Mosca S; Metro G; Rossi M; Orgera G; Scialpi M; Donini A
Gastroenterol Res Pract; 2017; 2017():4164130. PubMed ID: 28894464
[TBL] [Abstract][Full Text] [Related]
57. Comparison of Treatment Response and Survival Profiles Between Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Chinese Hepatocellular Carcinoma Patients: A Prospective Cohort Study.
Wen P; Chen SD; Wang JR; Zeng YH
Oncol Res; 2019 May; 27(5):583-592. PubMed ID: 31053181
[TBL] [Abstract][Full Text] [Related]
58. Clinical implications of C-reactive protein-albumin-lymphocyte (CALLY) index in patients with esophageal cancer.
Ma R; Okugawa Y; Shimura T; Yamashita S; Sato Y; Yin C; Uratani R; Kitajima T; Imaoka H; Kawamura M; Morimoto Y; Okita Y; Yoshiyama S; Ohi M; Toiyama Y
Surg Oncol; 2024 Apr; 53():102044. PubMed ID: 38335851
[TBL] [Abstract][Full Text] [Related]
59. Albumin-Bilirubin (ALBI) Grade-Based Nomogram for Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Ho SY; Hsu CY; Liu PH; Lee RC; Ko CC; Huang YH; Su CW; Hou MC; Huo TI
Dig Dis Sci; 2021 May; 66(5):1730-1738. PubMed ID: 32548811
[TBL] [Abstract][Full Text] [Related]
60. Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization.
Ke Q; Xiang F; Xiao C; Huang Q; Liu X; Zeng Y; Wang L; Liu J
BMC Cancer; 2021 Oct; 21(1):1117. PubMed ID: 34663242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
